Once a patient-specific dose is determined, an all-oral combination of revumenib plus decitabine/cedazuridine and venetoclax may be “very good” in AML.
Wei Ying Jen, MA, BM BCh, M Med, MRCP, FRCPath
Advertisement
Articles by Wei Ying Jen, MA, BM BCh, M Med, MRCP, FRCPath
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CancerNetwork
1
Poorer Outcomes Observed for Black Patients Undergoing Chemotherapy for AML
2
Epcoritamab Combo Significantly Improves Efficacy in 2L R/R Follicular Lymphoma
3
Early Efficacy Highlighted With Odronextamab/CHOP in Untreated DLBCL
4
Survival Benefit Seen With Cilta-Cel in Earlier Lines of Myeloma Treatment
5
